GSK plans to increase stakes in both India and Nigeria

Pharmaceuticals giant GlaxoSmithKline has announced a voluntary open offer to increase its holding in its publicly-listed Consumer Healthcare subsidiary in India.

Pharmaceuticals giant GlaxoSmithKline has announced a voluntary open offer to increase its holding in its publicly-listed Consumer Healthcare subsidiary in India.

The company also said it has come to an agreement on the terms of a proposal to increase its ownership in GlaxoSmithKline Consumer Nigeria, which manufactures, markets and distributes a wide range of Consumer Healthcare brands, to 80%.

Increasing stake in Indian subsidiaryGSK has made an offer to increase its stake in GlaxoSmithKline Consumer Healthcare from 43.2% to up to 75% at a price of INR 3,900 per share. This percentage would allow securities relations in India to maintain the minimum public shareholidng of 25% that enables the company to retain a public listing in the country.

GSK wants to acquire up to 13.39m shares, equal to 31.8% of the total outstanding shares, at a premium of about 28% to the closing price on Friday November 23rd. The total value of the transaction is potentialy £591m.

David Redfern, Chief Strategy Officer, GSK said: "GSK Consumer Healthcare is a well established business in India and its leading product, Horlicks, is an iconic household brand. This transaction represents a further step in GSK's strategy to invest in the world's fastest growing markets and, we believe, offers a liquidity opportunity at an attractive premium for existing shareholders."

The transaction will be funded through GSK's existing cash resources, will be earnings neutral for the first year and accretive thereafter and will not impact expectations for the group's long-term share buyback programme, it said.

Building stake in GlaxoSmithKline Consumer NigeriaThe group has agreed in principle to increase its stake in GlaxoSmithKline Consumer Nigeria from 46.4% to 80%, with the other 20% remaining a public shareholding, in line with the minimum requirement for a company to maintain a listing on the Nigerian Stock Exchange.

GSK will purchase around 321m shares in the company from public shareholders at an offer price of NGN 48 per share.

Approximately 70% of the company's revenue is from Consumer Healthcare Brands and 30% is from Pharmaceuticals and Vaccines.

The offer represents a premium of 28% to the company's closing share price on November 23rd.

David Redfern, Chief Strategy Officer, GSK said: "This Proposal to increase GSK's ownership of GlaxoSmithKline Consumer Nigeria reiterates our long term support of the Company's strategy and our confidence in the continuing growth prospects of the business."

The transaction will be funded through GSK's existing cash resources, will be modestly earnings accretive immediately, and will not impact expectations for the group's long-term share buyback programme.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

Investors are shunning UK stocks – but they might regret that in a year’s time
UK stockmarkets

Investors are shunning UK stocks – but they might regret that in a year’s time

There are a number of reasons why investors aren't buying UK stocks, says John Stepek. But they may want to rethink that strategy.
29 Sep 2020
Are we really in a stockmarket bubble?
US stockmarkets

Are we really in a stockmarket bubble?

The rise of “cash shell” companies, sky-high valuations – everything seems to point to a stockmarket bubble. But all may not quite be as it appears, s…
28 Sep 2020
Two commodities that could lie at the heart of the next resources bubble
Energy

Two commodities that could lie at the heart of the next resources bubble

Commodities tend to move in cycles. And if you can identify early on which ones are about to surge in demand, you can profit handsomely. Dominic Frisb…
30 Sep 2020